Companies › Taiho Pharmaceutical
5 active drug programs in 19 registered trials: 7 Phase 1, 7 Phase 2, 4 Phase 3, 1 Phase 4; Oncology, Hematology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zimberelimab (AB122) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Biliary Tract Cancer; Advanced or Metastatic Solid Tumor | Jun 2027 |
| Imatinib Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 1 | Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic … | Dec 2026 |
| Pimitespib HSP90 inhibitor | HSP90AA1, HSP90AB1 | Phase 1 | Gastrointestinal Stromal Tumors | Dec 2026 |
| ASTX030 (AZA + CED) DNA methyltransferase inhibitor (azacitidine) combined with cytidine deaminase inhibitor ( | DNMT1 | Phase 1 | Myelodysplastic Syndrome (MDS) | Dec 2027 |
| TAS0953/HM06 RET inhibitor | RET | Phase 1 | RET-altered Non Small Cell Lung Cancer | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04147533 | Imatinib | Phase 2 | Chronic Myeloid Leukemia, Chronic Phase | Oncology | Jun 2026 |
| NCT05277844 | Imatinib | Phase 2 | Oligometastatic Disease | Oncology | Nov 2026 |
| NCT05245968 | Pimitespib | Phase 1 | Gastrointestinal Stromal Tumors | Oncology | Dec 2026 |
| NCT05245968 | Imatinib | Phase 1 | Gastrointestinal Stromal Tumors | Oncology | Dec 2026 |
| NCT03844360 | Imatinib | Phase 4 | Hematological Neoplasms | Oncology | Dec 2026 |
| NCT05009927 | Imatinib | Phase 2 | Metastatic Gastrointestinal Stromal Tumor (GIST) | Oncology | Jan 2027 |
| NCT00044304 | Imatinib | Phase 2 | Eosinophilic Myeloid Neoplasm | Oncology | Mar 2027 |
| NCT04999761 | Zimberelimab (AB122) | Phase 1 | Advanced or Metastatic Solid Tumor | Oncology | Jun 2027 |
| NCT05493215 | Imatinib | Phase 2 | Gastrointestinal Stromal Tumors | Oncology | Dec 2027 |
| NCT04608110 | ASTX030 (AZA + CED) | Phase 1 | Myelodysplastic Syndrome (MDS) | Hematology | Dec 2027 |
| NCT06962254 | Imatinib | Phase 1 | Solid Tumor Cancer | Oncology | Mar 2028 |
| NCT05753384 | Imatinib | Phase 3 | Tyrosine Kinase Inhibitors | Oncology | Dec 2028 |
| NCT04933669 | Imatinib | Phase 2 | Progression-free Survival | Oncology | Dec 2029 |
| NCT04683250 | TAS0953/HM06 | Phase 1 | RET-altered Non Small Cell Lung Cancer | Oncology | Mar 2030 |
| NCT07710885 | Zimberelimab (AB122) | Phase 3 | Biliary Tract Cancer | Oncology | Apr 2030 |
| NCT07171203 | Imatinib | Phase 1 | Gastrointestinal Stromal Tumors | Oncology | Jul 2030 |
| NCT04307576 | Imatinib | Phase 3 | Leukemia, Acute Lymphoblastic | Oncology | Jun 2033 |
| NCT02413736 | Imatinib | Phase 3 | Sarcoma | Oncology | Jun 2033 |
| NCT06119789 | Imatinib | Phase 2 | Rare Malignant Neoplasm | Oncology | Nov 2033 |
Roche Chia Tai Tianqing Pharmaceutical Group Novartis Daiichi Sankyo Blueprint Medicines Eli Lilly Bayer Gossamer Bio USA Etnova Therapeutics Advenchen Laboratories
Nanjing Sanhome Pharmaceutical TORL Biotherapeutics Shandong Boan Biotechnology Taiho Oncology Chengdu New Radiomedicine Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.